E2020
Sponsors
Eisai Co., Ltd., Eisai Inc., Eisai Limited
Conditions
Alzheimer's Type DementiaDementia With Lewy Bodies (DLB)Dementia, Lewy BodyLewy Body Disease
Phase 2
A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
CompletedNCT00598650
Start: 2008-02-29End: 2011-03-31Updated: 2014-09-03
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
CompletedNCT01276353
Start: 2011-01-31End: 2012-04-30Updated: 2014-08-08
Phase 3
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
CompletedNCT01404169
Start: 2011-09-30End: 2014-09-30Updated: 2017-03-08
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
CompletedNCT01539031
Start: 2012-03-31End: 2015-03-31Updated: 2023-06-18